347 results on '"Ayzenberg, Ilya"'
Search Results
2. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management
3. KCNA2 IgG autoimmunity in neuropsychiatric diseases
4. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis
5. Schlafattacken, Hirnstammsyndrom und Gangstörung
6. Phoenix from the ashes: dramatic improvement in severe late-onset methylenetetrahydrofolate reductase (MTHFR) deficiency with a complete loss of vision
7. Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients
8. Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: A Multicenter Cohort Study.
9. Molecular dissection of an immunodominant epitope in Kv1.2-exclusive autoimmunity
10. Therapie antikörpervermittelter Enzephalomyelitiden: Strategien zur Behandlung der Neuromyelitis-optica-Spektrumerkrankung und der Myelooligodendrozytenglykoprotein-Antikörper-assoziierten Erkrankung
11. Cortical atrophy patterns in myelin oligodendrocyte glycoprotein antibody‐associated disease.
12. Neonatal B-Cell Levels and Infant Health in Newborns Potentially Exposed to Anti-CD20 Monoclonal Antibodies During Pregnancy or Lactation.
13. Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?
14. Multiple sclerosis is not associated with an increased risk for severe COVID-19: a nationwide retrospective cross-sectional study from Germany
15. Diabetes Mellitus Is a Possible Risk Factor for Nodo-paranodopathy With Antiparanodal Autoantibodies
16. Effects of IVIg treatment on autoantibody testing in neurological patients: marked reduction in sensitivity but reliable specificity
17. Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders
18. Molecular dissection of an immunodominant epitope in Kv1.2-exclusive autoimmunity.
19. Development of a Composite Score for the Clinical Assessment of Anti-IgLON5 Disease.
20. Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD.
21. In Vivo Measurement of Tau Depositions in Anti-IgLON5 Disease Using [18F]PI-2620 PET
22. Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients With Central Nervous System Demyelination
23. Autoimmune and Autoantibody-Associated Encephalomyelopathies
24. List of Contributors
25. Early immunotherapy is highly effective in IgG1/IgG4 positive IgLON5 disease
26. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients
27. Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: A cohort study from Germany
28. Inpatient care of neuromyelitis optica spectrum disorder in Germany: Nationwide analysis from 2010 to 2021
29. Novel variants in a patient with late-onset hyperprolinemia type II: diagnostic key for status epilepticus and lactic acidosis
30. Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders
31. Three cases of non-carryover fingolimod-PML: Is the risk in Japan increased?
32. Retrospective comparison clinical presentation and outcome of Natalizumab and Fingolimod-associated PML (P7-3.004)
33. Real-world data on eculizumab treatment in NMOSD: high efficacy and potential challenges (P13-5.017)
34. Cognitive impairment in MOGAD is associated with ADEM-like episodes and deep grey matter atrophy (S40.006)
35. Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF
36. List of Contributors
37. Neuromyelitis Optica Spectrum Disorders
38. General principles and escalation options of immunotherapy in autoantibody-associated disorders of the CNS
39. Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study)
40. Humoral COVID-19 vaccine response in patients with NMOSD/MOGAD during anti-IL-6 receptor therapy compared to other immunotherapies
41. Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Diseases
42. sj-docx-1-msj-10.1177_13524585231151212 – Supplemental material for Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study)
43. Twig-like Middle Cerebral Artery: a Seldom Vessel Anomaly of Important Relevance
44. Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage
45. Cross-sectional analysis of clinical aspects in patients with long-COVID and post-COVID syndrome
46. Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model
47. Charles Bonnet syndrome successfully treated with levetiracetam
48. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study
49. Headache yesterday in Russia: its prevalence and impact, and their application in estimating the national burden attributable to headache disorders
50. Quantification of individual remyelination during short-term disease course by synthetic magnetic resonance imaging
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.